Floatz logo

Iadademstat

Myelodysplastic Syndrome/Acute Myeloid Leukemia

OHSU Knight Cancer InstituteSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Azacitidine
City of Hope Medical Center
Phase 2/3BB
Decitabine
National Cancer Institute (NCI)
Phase 2/3B
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2/3B
Nivolumab
National Cancer Institute (NCI)
Phase 2/3B
Midostaurin
National Cancer Institute (NCI)
Phase 2/3B

View all 21 →

Same molecule, other indications

Iadademstat is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
neuroendocrine carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
lung cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →